On June 7, 2021 Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, reported that Stanley C. Erck, President and Chief Executive Officer, will participate in a panel discussion at the BIO International Convention 2021 on June 14 (Press release, Novavax, JUN 7, 2021, View Source [SID1234583667]). BIO Digital 2021 is hosted by the Biotechnology Innovation Organization (BIO) and is taking place June 10-11 and June 14-18. Novavax’ COVID-19 vaccine candidate, NVX-CoV2373, will be a topic of discussion.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Stanley C. Erck headshot
Panel details are as follows:
Date:
Monday, June 14, 2021
Time:
3:00 p.m. – 3:45 p.m. Eastern Time (ET)
Title:
Global Pandemic Preparedness – It Takes a Globe….
Moderator:
Phyllis Arthur, Vice President, Infectious Diseases and Diagnostics Policy, Biotechnology Innovation Organization
Panelists:
Stanley C. Erck, President and Chief Executive Officer, Novavax
Amanda Glassman, Executive Vice President, Chief Executive Officer, CGD Europe and Senior Fellow, Center for Global Development
Richard Hatchett, M.D., Chief Executive Officer, Coalition for Epidemic Preparedness
Rajeev Venkayya, M.D., President, Global Vaccine Business Unit, Takeda Pharmaceuticals
For more information or to register for the meeting, visit: View Source
About NVX-CoV2373
NVX-CoV2373 is a protein-based vaccine candidate engineered from the genetic sequence of the first strain of SARS-CoV-2, the virus that causes COVID-19 disease. NVX-CoV2373 was created using Novavax’ recombinant nanoparticle technology to generate antigen derived from the coronavirus spike (S) protein and is adjuvanted with Novavax’ patented saponin-based Matrix-M to enhance the immune response and stimulate high levels of neutralizing antibodies. NVX-CoV2373 contains purified protein antigen and can neither replicate, nor can it cause COVID-19. In preclinical studies, NVX-CoV2373 induced antibodies that blocked the binding of spike protein to cellular receptors and provided protection from infection and disease. It was generally well-tolerated and elicited robust antibody response in Phase 1/2 clinical testing.
NVX-CoV2373 is being evaluated in two pivotal Phase 3 trials: a trial in the U.K. that demonstrated efficacy of 96.4% against the original virus strain, 86.3% against the B.1.1.7/501Y.V1 variant and 89.7% overall; and the PREVENT-19 trial in the U.S. and Mexico that began in December 2020. It is also being tested in two ongoing Phase 2 studies that began in August 2020: A Phase 2b trial in South Africa that demonstrated 48.6% efficacy against a newly emerging escape variant first described in South Africa, and a Phase 1/2 continuation in the U.S. and Australia.
NVX-CoV2373 is stored and stable at 2°- 8°C, allowing the use of existing vaccine supply chain channels for its distribution. It is packaged in a ready-to-use liquid formulation in 10-dose vials.
About Matrix-M Adjuvant
Novavax’ patented saponin-based Matrix-M adjuvant has demonstrated a potent and well-tolerated effect by stimulating the entry of antigen-presenting cells into the injection site and enhancing antigen presentation in local lymph nodes, boosting immune response.